WebApr 10, 2024 · A rating of 81 puts Greenwich Lifesciences Inc ( GLSI) near the top of the Healthcare sector according to InvestorsObserver . Greenwich Lifesciences Inc's score … WebGreenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer … Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical … GP2 immunotherapy trains a patient’s T cells to recognize and destroy … The current, ongoing trial is a Phase III clinical trial registered with the name, … Company Profile. Business Description: Greenwich LifeSciences (the … about. management team; board of directors; technology. our gp2 cancer … Dr. Thompson has over 30 years of experience in pharmaceutical and … GP2 is a nine amino acid transmembrane peptide of the HER2/neu protein. … Understand cancer and immunotherapy, cancer’s escape from … Greenwich LifeSciences Provides Year End Update. Dec 1, 2024 6:00am EST. … Company Info - Greenwich LifeSciences, Inc. (GLSI) GP2
Greenwich LifeSciences, Inc. : HC Wainwright toujours à l
WebApr 14, 2024 · Greenwich LifeSciences, Inc. has a 12-month low of $6.82 and a 12-month high of $21.50. The firm’s 50-day moving average price is $14.92 and its two-hundred day moving average price is $13.48. WebLegal Name Greenwich LifeSciences, Inc. Stock Symbol NASDAQ:GLSI ; Company Type For Profit; Contact Email [email protected]; Phone Number (832) 819-3232; florence daily times
H.C. Wainwright Sticks to Its Buy Rating for Greenwich …
WebApr 10, 2024 · Greenwich LifeSciences Inc is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients. WebSep 6, 2024 · Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data. Greenwich LifeSciences' CEO, Snehal Patel, runs this company almost all by ... WebApr 14, 2024 · Whilst it may not be a huge deal, we thought it was good to see that the Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO, CFO & Director, Snehal Patel, recently bought US$62k worth of stock, for US$12.42 per share.Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a … florence daily news